INDICATION Lutathera ® is a radiolabeled somatostatin analog indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including ...

The FDA approved lutetium Lu 177 dotatate for the treatment of pediatric patients aged 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors ...

Background: Radiolabeled somatostatin receptor 2 (sstr2) antagonists have shown higher tumor uptake and tumor-to-organ ratios than agonists in preclinical models. We performed a phase I study to ...

Background: Targeted therapy of NENs based on the presence of SSTRs fills a unique niche in tumor biology and clinical treatment of patients with solid tumors. SSTRs have multiple isoforms and are ...

The FDA granted fast track designation to ITM-11 for treatment of gastroenteropancreatic neuroendocrine tumors. ITM-11 (ITM Isotope Technologies Munich SE) consists of two components: lutetium-177 ...

SOM230 (Pasireotide®, Novartis, Basel, Switzerland) is a novel multireceptor ligand analogue that has high affinity for four of the five somatostatin receptor subtypes (sst 1, 2, 3 and sst 5 ...

Edotreotide binds to these receptors and places the medical radioisotope n.c.a. lutetium-177 directly onto the diseased neuroendocrine cells so that it accumulates at the tumor site. N.c.a ...

“We are eager to share our latest pipeline progress at NANETS 2024. Crinetics is committed to the neuroendocrine tumor community, and we are now utilizing our world class drug discovery and ...

Significant investments in neuroendocrine disease treatments and the continuous improvement of diagnostic tools, such as ...